Expansion of the application of cystic fibrosis drugs
-
Last Update: 2020-06-03
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Business, March 5 (UPI) -- Vertex Incannounced that the FDA has approved a new drug application for its Kalydeco (ivacaftor) for patients aged 6 years or older who have mutated cystic fibrosis (CF) in one of the remaining eight variants of the cystic fibrosis transmembrane conductivity regulatory geneKalydeco was first approved in January 2012 for CF patients aged 6 years or older with at least one copy of the G551D mutationAs a result of this supplementary application, Kalydeco is now available for CF patients with the following nine mutations: G551D, G178R, S549N, S549R, G551S, G1244E, S1251N, S1255P, and G1349DIn the U.S., there are currently about 150 CF patients aged 6 and older with one of the remaining eight mutations, and Kalydeco is adapting to their treatment needsKalydeco is a chemical lycited drug (150mg oral tablet) developed by Vertex Pharmaceuticals and CFIt is one of the world's most expensivedrug, costing up to $300,000 a year and has been criticised
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
